Sugi Predict

Sugi Predict / Compounds / SCHEMBL22092151

SCHEMBL22092151

SCHEMBL22092151

COc1ccc(CO/N=C(\C)c2cccc(OCC(=O)O)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 10/20 0.59
▸ PPARA Q07869 10/20 0.59
▸ LMNA P02545 1/20 0.54
▸ SMPD1 P17405 1/20 0.53
▸ S1PR1 P21453 2/20 0.52
▸ PKM P14618 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ FFAR1 O14842 2/20 0.47
▸ PPARD Q03181 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22092152 1.00 PPARG (0.59) PPARGPPARALMNASMPD1S1PR1
SCHEMBL29451170 1.00 PPARG (0.59) PPARGPPARALMNASMPD1S1PR1
SCHEMBL29451160 0.90 PPARA (0.56) PPARGPPARASMPD1S1PR1NPC1
SCHEMBL22092176 0.89 MAOB (0.59) PPARGPPARAS1PR1PKMHTT
SCHEMBL22092156 0.89 MAOB (0.59) PPARGPPARALMNASMPD1NPC1
SCHEMBL22092155 0.89 MAOB (0.59) PPARGPPARALMNASMPD1NPC1
SCHEMBL22092178 0.89 MAOB (0.59) PPARGPPARAS1PR1PKMHTT
SCHEMBL22092363 0.87 S1PR1 (0.62) PPARGPPARAS1PR1PKMHTT
SCHEMBL22092365 0.87 S1PR1 (0.62) PPARGPPARAS1PR1PKMHTT
SCHEMBL22092145 0.86 PPARG (0.48) PPARGPPARANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12246002-B2 Pharmaceutical composition for prevention or treatment of circadian rhythm-related disorders, comprising oxyiminomethylbenzene derivative as active ingredient KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2025-03-11 — — US claimed
US-20220062215-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2022-03-03 — — US claimed
WO-2020122380-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT 고려대학교 산학협력단 2020-06-18 — — WO claimed
WO-2020122380-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT 고려대학교 산학협력단 2020-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220062215-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT PER2, CRY1, CRY2 PPARG 630/4885PPARA 920/4885LMNA 2572/4885
US-12246002-B2 Pharmaceutical composition for prevention or treatment of circadian rhythm-related disorders, comprising oxyiminomethylbenzene derivative as active ingredient PER2, CRY1, CRY2 PPARG 630/4885PPARA 920/4885LMNA 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.